Vivoryon Therapeutics N.V. (LON:0R3M)

London flag London · Delayed Price · Currency is GBP · Price in EUR
1.798
+0.004 (0.22%)
At close: Apr 28, 2025
124.75%
Market Cap 39.55M
Revenue (ttm) n/a
Net Income (ttm) -17.01M
Shares Out n/a
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11
Average Volume 250
Open 1.770
Previous Close 1.794
Day's Range 1.770 - 1.798
52-Week Range 0.500 - 19.400
Beta n/a
RSI 45.39
Earnings Date Apr 24, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutic... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1997
Employees 15
Stock Exchange London Stock Exchange
Ticker Symbol 0R3M
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.